News and Events

Celebrating CCR Careers: David D. Roberts, Ph.D.

David D. Roberts, Ph.D., a biochemist who identified a new pathway that controls cell responses to stress and developed approaches to improve cancer therapy by shutting it down, announces his retirement from the NCI.

Clinical trial researching drug therapy for neuroendocrine neoplasms

A trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is studying a new drug for neuroendocrine neoplasms, a group of rare cancers.

Master regulators flip the switch on neuroblastoma’s developmental state

Waves of regulatory changes can transform self-renewing neuroblastoma cells into neurons.

Benign nail condition linked to rare syndrome that greatly increases cancer risk

Researchers from CCR and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) discovered the presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors. The study suggests conducting nail evaluation of affected patients and at-risk family members.

New AI tool classifies brain tumors using images of tumor slides

A new artificial intelligence model has been found to be highly effective at identifying brain tumor subtypes — with 95% accuracy — simply by analyzing a standard pathology image of the tumor tissue.

New research identifies a protein essential to maintaining chromosomal stability

Researchers discovered how overproduction of a protein called CENP-A can lead to chromosomal abnormalities, which are found in many types of cancer.

New database of sarcoma cell line data will drive rare cancer research

CCR researchers have developed the largest publicly accessible sarcoma cell line database called Sarcoma CellMinerCDB. The tool merges previously available and new sarcoma cell line data that can be used to identify new therapeutic targets for these cancers.

Clinical trial researching combination therapy for solid tumors

A trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, is researching white blood cell gene therapy and vaccine therapy for certain metastatic cancers.

Three CCR researchers elected to the National Academy of Sciences

Steven A. Rosenberg, M.D, Ph.D., Chief of the Surgery Branch, Giorgio Trinchieri, M.D., Chief of the Laboratory of Integrative Cancer Immunology, and Sandra L. Wolin, M.D., Ph.D., Chief of the RNA Biology Laboratory, were elected as 2024 members of the National Academy of Sciences in recognition of their distinguished and continuing achievements in original research. The Academy is committed to furthering science in America, and its members are outstanding contributors to the international scientific community.

Clinical trial researching detection methods for multiple myeloma

A trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is studying a radiotracer that may be a useful detection method for multiple myeloma.

Breadcrumb